EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access

Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis

Wilbur H Chen iD, Charmagne G Beckett, Mohamed Al-Ibrahim, Reva Datar iD, Michael J Sikorski iD, Yuanyuan Liang, Marcela F Pasetti iD, Marcelo B Sztein iD, Rezwanul Wahid iD, Sharon M Tennant iD, Raphael Simon, Scott M Baliban iD und 8 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag156 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Wilbur H Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Immunogenicity, Vaccine, Salmonella enteritidis, Salmonella Infections, Salmonella typhi. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive disease caused by typhoid and nontyphoidal Salmonella (NTS) is a threat confronting young children in sub-Saharan Africa. We are developing a trivalent Salmonella conjugate vaccine (TSCV) consisting of typhoid Vi conjugate and core-O-polysaccharide conjugates from 2 invasive NTS serovars (S. Typhimurium and S. Enteritidis).

Methods

We conducted a randomized-controlled Phase 1/2a trial assessing the safety and immunogenicity of a full-strength TSCV (FS; 25 µg of all 3 polysaccharides), half-strength TSCV (HS; 25 µg of Vi and 12.5 µg of both NTS polysaccharides), dilutional half-strength TSCV (dilHS; 12.5 µg of all 3 polysaccharides), or placebo. Local and systemic adverse events were recorded and blood was collected for serum antibody and antibody-secreting cells (ASCs).

Results

In total, 80 evaluable participants aged 20–47 years were enrolled. All vaccines were well tolerated; mild injection site pain and fatigue were the most common reactions reported. Serum antibody and ASC responses to the 3 primary polysaccharide antigens were robust, ranging between 85% and 100% response rates, with no statistically significant difference between the 3 formulations. No placebo recipients manifested significant antibody or ASC responses.

Conclusions

These data encourage the further development of TSCV to address a pressing public health problem in young children of sub-Saharan Africa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenicity, VaccineSalmonella enteritidisSalmonella InfectionsSalmonella typhiSalmonella typhimuriumSalmonella VaccinesAdultFemaleHumansMaleMiddle AgedYoung AdultAntibodies, BacterialPolysaccharides, BacterialTyphoid FeverVaccines, Conjugate

Stichwörter der Autor:innen

Salmonellaimmunitynontyphoidal Salmonellatyphoidvaccine

Substanzen

Antibodies, BacterialPolysaccharides, BacterialSalmonella VaccinesVaccines, Conjugate

Autor:innen und Institutionen

  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, USA.
  • Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Fina Biosolutions LLC, Rockville, Maryland, USA.
  • Bharat Biotech International Ltd., Hyderabad, Telangana, India.

ORCID-Profile: Wilbur H Chen, Reva Datar, Michael J Sikorski, Marcela F Pasetti, Marcelo B Sztein, Rezwanul Wahid, Sharon M Tennant, Scott M Baliban, James E Galen, Andrew Lees, Raches Ella, Krishna M Ella, Myron M Levine

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • Wellcome Trust

Zitieren

APA

Chen, W. H., Beckett, C. G., Al-Ibrahim, M., Datar, R., Sikorski, M. J., Liang, Y., Pasetti, M. F., Sztein, M. B., Wahid, R., Tennant, S. M., Simon, R., Baliban, S. M., Galen, J. E., Lees, A., Ella, R., Mohan, K., Naidu, M. G., Rao, D. Y., Ella, K. M., & Levine, M. M. (2026). Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag156

Vancouver

Chen WH, Beckett CG, Al-Ibrahim M, Datar R, Sikorski MJ, Liang Y, et al. Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag156

BibTeX
@article{Chen2026,
  author = {Chen, Wilbur H and Beckett, Charmagne G and Al-Ibrahim, Mohamed and Datar, Reva and Sikorski, Michael J and Liang, Yuanyuan and Pasetti, Marcela F and Sztein, Marcelo B and Wahid, Rezwanul and Tennant, Sharon M and Simon, Raphael and Baliban, Scott M and Galen, James E and Lees, Andrew and Ella, Raches and Mohan, Krishna and Naidu, M Gangadhara and Rao, D Yogeswara and Ella, Krishna M and Levine, Myron M},
  title = {Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag156}
}
Kostenlos starten →